CRISPR Therapeutics (CRSP) Says EPO to Grant CRISPR/Cas Gene Editing Patent – StreetInsider.com
McGill Tribune |
CRISPR Therapeutics (CRSP) Says EPO to Grant CRISPR/Cas Gene Editing Patent
StreetInsider.com CRISPR Therapeutics (NASDAQ: CRSP) reported that the European Patent Office (EPO) has announced its intention to grant a patent broadly covering CRISPR’s in-licensed gene editing technology. The claims are directed to the CRISPR/Cas9 single-guide … What’s the deal with CRISPR?McGill Tribune European Patent Office to Grant Broad Claims on Patent Covering …Digital Journal |
Endpoints News |
Bristol-Myers Squibb (BMY), CRI, and Parker Institute for Cancer …
StreetInsider.com Get instant alerts when news breaks on your stocks. Claim your 2-week free trial to StreetInsider Premium here. The Parker Institute for Cancer Immunotherapy, … Parker Institute, BMS, and CRI Partner on Immuno-Oncology ResearchGenetic Engineering & Biotechnology News BMS seeks leg-up in immuno-oncology with Parker Institute and CRI pactFierceBiotech |
Endpoints News |
A gene therapy pioneer moves from Biogen to Regenxbio, staying focused on gene therapy 2.0
Endpoints News Olivier Danos’ arrival as head of Biogen’s gene therapy group two-and-a-half years ago signaled an important shift in the big biotech’s R&D focus. In swift order Biogen executed a partnership with the San Raffaele-Telethon Institute for Gene Therapy … Regenxbio (RGNX) Names Olivier Danos, Ph.D as Chief Scientific OfficerStreetInsider.com |